LTI-214 / Leukogene Therap - LARVOL DELTA

A superantigen-based MHC class II-targeted cancer immunotherapy for the treatment of acute myeloid leukemia. (PubMed, Blood Cancer J) - "Finally, M2T-CD33 was enhanced by combinations with anti-PD-1 therapy. These experiments demonstrate the preclinical potential of M2T-CD33 in AML and emphasize the importance of MHCII for cancer immunotherapy."

IO biomarker • Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD4 • CD8

U.S. FDA Grants Orphan Drug Designation to Leukogene Therapeutics’ M2T-CD33 (LTI-214) for the Treatment of Acute Myeloid Leukemia (Businesswire)

Orphan drug • Acute Myelogenous Leukemia